STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, sturdy preclinical effects for a new COVID-19 vaccine, made by the team of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint undertaking partner AdaptVac and the Avoid-nCoV consortium, was printed. Primarily based on these success, a scientific trial application (CTA) for a scientific Phase I/II research for the COVID-19 vaccine has been submitted.
About the preclinical outcomes
Readouts from the information display that ABNCoV2 has the opportunity to be the ideal-in-class COVID-19 vaccine with a far more than 100-fold greater level of neutralizing antibodies when compared with printed preclinical animal info from at the moment approved COVID-19 vaccines, these kinds of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The total paper is offered on the web and can be read right here.
About the CTA
The Scientific trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) primarily based COVID-19 vaccine was submitted to the Central Committee on Investigate Involving Human Topics (CCMO) in the Netherlands final week. It is envisioned to be approved beneath a COVID-19 quickly-monitor critique progress. This can be witnessed as a different important milestone next the November 2020 announcement of the thriving GMP producing of the vaccine. ExpreS2ion expects to current preliminary scientific Phase I/IIa effects before end of Q1 2021.
Since March 2020, Attana has been aiding the group of Prof. Ali Salanti at the College of Copenhagen in the progress of this COVID-19 vaccine with two of Attana’s QCM Biosensors mixed with investigate intelligence. As can be viewed in the paper printed, Attana’s technology has foremost been made use of to evaluate kinetic interactions among RBD antigens and CLP-RBD to hACE2. In addition, Attana and ExpreS2ion recently set up a strategic partnership which include a supply settlement of proteins. In addition, Attana engineering has been used to high-quality regulate the vaccine for the IND submission.
Attana CEO Teodor Aastrup comments:
“I’m thrilled for our companions sake and for the upcoming of vaccine advancement and wish to congratulate all get-togethers associated for reaching such exciting outcomes. I’m now searching ahead to discover this collaboration further and to ideally work additional intently with both equally Prof. Salanti and the crew at ExpreS2ion in the in the vicinity of time long run.”
For far more information and facts, you should make contact with:
+46 () 8 674 57 00
The Board of administrators for Attana contemplate that the info in this press launch is not likely to have a sizeable impact on the share price but is of general curiosity for the shareholders and that’s why ought to be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Given that then, Attana has made proprietary label absolutely free biosensors for biochemical, crude, sera, and mobile-primarily based assays and the Attana Virus Analytics (AVA) system, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research products and services are applied by Massive Pharma, biotech firms and academic institutions in just the lifetime sciences. To understand a lot more about our most current expert services and items, be sure to visit www.attana.se or call [email protected]
This data was introduced to you by Cision http://information.cision.com
The pursuing documents are accessible for down load: